There is no cure for diabetes, and current treatments are insufficient in controlling blood sugars for many patients. Transplantation of insulin-secreting tissues promises to be an effective treatment, and some success has been realized by transplanting islets from cadaveric donors. However, isolated cadaveric islets are scarce and suffer from highly variable quality. A solution to this problem is to generate a renewable and consistent supply of SC-islets, at sufficiently large scale, from pluripotent stem cells for research and development and ultimately as a cell therapy. The Millman laboratory at WUStL has developed a robust, manual, bench-scale process for generating cell preparations with islet-like characteristics from iPSCs. We are automating and scaling this manual process on the ARMI|BioFabUSA Tissue Foundry manufacturing platform to generate a standardized preparation of well-characterized and quality controlled SC-islets for distribution across JDRF-funded laboratories. Ultimately, we plan to produce human SC-islets in a scalable, automated process under GMPs for human therapeutics.